Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer

Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative

(2012) Alfonso Quintas-Cardama et al.   Anti-Cancer Agents in Medicinal Chemistry

Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

(2011) F. R. Kona et al.   CURRENT CANCER DRUG TARGETS

Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome

(2011) B. Cvek   CURRENT CANCER DRUG TARGETS

Overcoming Taxane and Anthracycline Resistance

(2010) Amelia Zelnak   Breast Journal

Redox platforms in cancer drug discovery and development

(2010) Kenneth D Tew et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study

(2010) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities

(2009) Georg T. Wondrak   ANTIOXIDANTS & REDOX SIGNALING

Glutathione dysregulation and the etiology and progression of human diseases

(2009) Nazzareno Ballatori et al.   BIOLOGICAL CHEMISTRY

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome

(2009) A. Raza et al.   BLOOD

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

(2009) Steven J. Cohen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase

(2009) Frederick H. Hausheer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase 3 randomised study of canfosfamide (Telcyta®, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer

(2009) I. Vergote et al.   EUROPEAN JOURNAL OF CANCER

Darinaparsin: a novel organic arsenical with promising anticancer activity

(2009) Koren K Mann et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma

(2009) Jennifer Wu et al.   INVESTIGATIONAL NEW DRUGS

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer

(2009) Stacy Moulder et al.   INVESTIGATIONAL NEW DRUGS

Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer

(2009) Lecia V. Sequist et al.   Journal of Thoracic Oncology

Redox Regulation of Cell Survival

(2008) Dunyaporn Trachootham et al.   ANTIOXIDANTS & REDOX SIGNALING

Mechanisms of ROS modulated cell survival during carcinogenesis

(2008) J.S. Clerkin et al.   CANCER LETTERS

Dual Actions Involved in Arsenite-Induced Oxidative DNA Damage

(2008) Xu-Jun Qin et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Motexafin Gadolinium for the Treatment of Metastatic Renal Cell Carcinoma: Phase II Study Results

(2008) Robert J. Amato et al.   Clinical Genitourinary Cancer

NOV-002, a mimetic of glutathione disulfide

(2008) Danyelle M Townsend et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Motexafin Gadolinium Combined With Prompt Whole Brain Radiotherapy Prolongs Time to Neurologic Progression in Non–Small-Cell Lung Cancer Patients With Brain Metastases: Results of a Phase III Trial

(2008) Minesh P. Mehta et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Further insights into the mechanism of the reaction of activated bleomycin with DNA

(2008) M. S. Chow et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of BSO (L-buthionine-S,R-sulfoximine)-induced cytotoxic effects in neuroblastoma

(2007) Barbara Marengo et al.   FREE RADICAL BIOLOGY AND MEDICINE